TELO — Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$1.10
-$0.02 (-1.79%)
Telomir Pharmaceuticals, Inc. Common Stock (TELO) is a biotechnology company listed on NASDAQ. It is led by Erez Aminov, based in 100 SE 2nd Street, Miami, FL, United States, 33131. Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Net income was -$1.1M. TELO currently screens at market cap $86.0M.
Use this TELO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TELO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TELO SEC filings page. Lician reads the product cache first so this HTML stays unique to Telomir Pharmaceuticals, Inc. Common Stock even when a live quote feed is slow.
About Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
TELO Key Statistics
Market Cap
$85.97M
Volume
69,002
Previous Close
$1.18
Day Range
$1.14 – $1.20
P/B Ratio
17.67
EPS
$0.56
Revenue
$0.00
Net Income
-$16.53M
Gross Profit
$0.00
Free Cash Flow
$0.00
TELO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$16.53M | -$13.07M | -$854.15K |
| EPS (Diluted) | $0.56 | $0.48 | -$0.03 |
Total Assets
$1.32M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.27M
Operating Cash Flow
-$5.07M
Free Cash Flow
$0.00
Telomir Pharmaceuticals, Inc. Common Stock Company Information
- Chairman of the Board & CEO
- Erez Aminov
- Headquarters
- 100 SE 2nd Street, Miami, FL, United States, 33131
- Website
- telomirpharma.com
- Phone
- 786 396 6723
- IPO / Founded
- 2024-02-09
- Sector
- Healthcare
- Industry
- Biotechnology